{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:05:48Z","timestamp":1794470748136,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA273319"],"award-info":[{"award-number":["R01CA273319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA256973"],"award-info":[{"award-number":["R01CA256973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA290438"],"award-info":[{"award-number":["R01CA290438"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R50CA305093"],"award-info":[{"award-number":["R50CA305093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA200466"],"award-info":[{"award-number":["U01CA200466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is the most common adult primary brain malignancy. Recent studies demonstrate that temozolomide (TMZ) facilitates the persistence of quiescent glioma stem cells (GSCs), which are responsible for GBM recurrence. An ideal therapy should eradicate both proliferating cells and GSCs. Abexinostat (Abx), a histone deacetylase inhibitor, was identified through connectivity mapping to target the specific GBM signature. Here, we demonstrate the anti-proliferative effect of Abx on both differentiated cells and GSCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using patient-derived tumor cultures (PDCs) to test Abx in vitro, ATAC-seq identified chromatin accessibility. Single-spheroid and alkaline phosphatase staining assays were used to test stem cell self-renewal. Aldehyde dehydrogenase activity distinguished mesenchymal GSCs. The efficacy of Abx with TMZ was evaluated in GSC-expressing CK9751 PDC and mesenchymal patient-derived xenografts (PDXs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In PDCs (CK9495 and CK9751), Abx decreased the DNA repair machinery (RAD51, CHK1, Ku70, and MGMT) and induced apoptosis. Focused ATAC-seq analysis for promoters of DNA repair (RAD51, Ku70, CHK1, and BRCA1) and stemness (CD44, KLF4, c-Myc, and BMI1) revealed Abx decreased chromatin accessibility. Abx decreased stem cell self-renewal and reduced the mesenchymal stem cell signature (CD44, ALDH1A3 expression, and ALDH1 activity) in vitro GBM models. Abx reduced tumor growth and stemness markers in CK9751 PDC and mesenchymal PDXs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Abx reduced both DNA repair machinery and GSC markers by decreasing chromatin accessibility. Abx reduced tumor growth and mesenchymal GSCs in vitro and in vivo in GBM PDC and PDX models, supporting Abx\u2019s potential to prevent GSC-mediated therapy resistance and improve patient survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag193","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:50:02Z","timestamp":1787140202000},"source":"Crossref","is-referenced-by-count":1,"title":["Abexinostat attenuates temozolomide-resistant glioma stem cells"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8632-6037","authenticated-orcid":false,"given":"Balaji","family":"Perumalsamy","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-3048","authenticated-orcid":false,"given":"Raghupathy","family":"Vengoji","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-3226","authenticated-orcid":false,"given":"Anand","family":"Thiraviyam","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0804-3625","authenticated-orcid":false,"given":"Indumati","family":"Ramireddy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-1878","authenticated-orcid":false,"given":"Poonam","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-0528","authenticated-orcid":false,"given":"Ashu","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-5827","authenticated-orcid":false,"given":"Kavita","family":"Mallya","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-1167","authenticated-orcid":false,"given":"Afshin","family":"Salehi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-3443","authenticated-orcid":false,"given":"Sushil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-3687","authenticated-orcid":false,"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-193X","authenticated-orcid":false,"given":"Moorthy P","family":"Ponnusamy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-9317","authenticated-orcid":false,"given":"Surinder K","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-3409","authenticated-orcid":false,"given":"Nicole","family":"Shonka","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]},{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026091211370571000_noag193-B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/carcin\/bgy171","article-title":"Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells","volume":"40","author":"Vengoji","year":"2019","journal-title":"Carcinogenesis"},{"key":"2026091211370571000_noag193-B2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2026091211370571000_noag193-B3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1476-4598-10-128","article-title":"Chemoresistance of glioblastoma cancer stem cells--much more complex than expected","volume":"10","author":"Beier","year":"2011","journal-title":"Mol Cancer"},{"key":"2026091211370571000_noag193-B4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI89587","article-title":"Overcoming therapeutic resistance in glioblastoma: the way forward","volume":"127","author":"Osuka","year":"2017","journal-title":"J Clin Invest"},{"key":"2026091211370571000_noag193-B5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"key":"2026091211370571000_noag193-B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-5-67","article-title":"Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma","volume":"5","author":"Liu","year":"2006","journal-title":"Mol Cancer"},{"key":"2026091211370571000_noag193-B7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/0008-5472.CAN-08-2741","article-title":"Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature","volume":"69","author":"Charafe-Jauffret","year":"2009","journal-title":"Cancer Res"},{"key":"2026091211370571000_noag193-B8","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res"},{"key":"2026091211370571000_noag193-B9","doi-asserted-by":"publisher","first-page":"e1223","DOI":"10.1038\/cddis.2014.188","article-title":"Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo","volume":"5","author":"Signore","year":"2014","journal-title":"Cell Death Dis"},{"key":"2026091211370571000_noag193-B10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"2026091211370571000_noag193-B11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1620\/tjem.226.267","article-title":"Knockdown of checkpoint kinase 1 is associated with the increased radiosensitivity of glioblastoma stem-like cells","volume":"226","author":"Wu","year":"2012","journal-title":"Tohoku J Exp Med"},{"key":"2026091211370571000_noag193-B12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2017.12.005","article-title":"HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH\/Gli1 signaling pathway","volume":"415","author":"Yang","year":"2018","journal-title":"Cancer Lett"},{"key":"2026091211370571000_noag193-B13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13046-021-02135-x","article-title":"Differential gene expression-based connectivity mapping identified novel drug candidate and improved temozolomide efficacy for glioblastoma","volume":"40","author":"Vengoji","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026091211370571000_noag193-B14","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-13-0877","article-title":"The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression","volume":"19","author":"Salvador","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026091211370571000_noag193-B15","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1038\/s41388-022-02493-6","article-title":"Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma","volume":"41","author":"Lakshmanan","year":"2022","journal-title":"Oncogene"},{"key":"2026091211370571000_noag193-B16","doi-asserted-by":"publisher","first-page":"217355","DOI":"10.1016\/j.canlet.2024.217355","article-title":"PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer","volume":"609","author":"Muniyan","year":"2025","journal-title":"Cancer Lett"},{"key":"2026091211370571000_noag193-B17","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1038\/s41467-023-43373-1","article-title":"Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer","volume":"14","author":"He","year":"2023","journal-title":"Nat Commun"},{"key":"2026091211370571000_noag193-B18","doi-asserted-by":"publisher","first-page":"19482","DOI":"10.1073\/pnas.0707828104","article-title":"HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination","volume":"104","author":"Adimoolam","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091211370571000_noag193-B19","doi-asserted-by":"publisher","first-page":"1436563","DOI":"10.3389\/fcell.2024.1436563","article-title":"How to sensitize glioblastomas to temozolomide chemotherapy: a gap-centered view","volume":"12","author":"Miramova","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026091211370571000_noag193-B20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"2026091211370571000_noag193-B21","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/stem.231","article-title":"Klf4 interacts directly with Oct4 and Sox2 to promote reprogramming","volume":"27","author":"Wei","year":"2009","journal-title":"Stem Cells"},{"key":"2026091211370571000_noag193-B22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/stem.143","article-title":"KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells","volume":"27","author":"Chan","year":"2009","journal-title":"Stem Cells"},{"key":"2026091211370571000_noag193-B23","doi-asserted-by":"publisher","first-page":"e3769","DOI":"10.1371\/journal.pone.0003769","article-title":"c-myc is required for maintenance of glioma cancer stem cells","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS One"},{"key":"2026091211370571000_noag193-B24","doi-asserted-by":"publisher","first-page":"8884","DOI":"10.1523\/JNEUROSCI.0968-09.2009","article-title":"BMI1 sustains human glioblastoma multiforme stem cell renewal","volume":"29","author":"Abdouh","year":"2009","journal-title":"J Neurosci"},{"key":"2026091211370571000_noag193-B25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm.4415","article-title":"Targeting glioma stem cells through combined BMI1 and EZH2 inhibition","volume":"23","author":"Jin","year":"2017","journal-title":"Nat Med"},{"key":"2026091211370571000_noag193-B26","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","article-title":"Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3","volume":"110","author":"Mao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091211370571000_noag193-B27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2014.01.005","article-title":"Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth","volume":"14","author":"Pietras","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2026091211370571000_noag193-B28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/neuros\/nyw026","article-title":"The pluripotent stem-cell marker alkaline phosphatase is highly expressed in refractory glioblastoma with DNA hypomethylation","volume":"80","author":"Iwadate","year":"2017","journal-title":"Neurosurgery"},{"key":"2026091211370571000_noag193-B29","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026091211370571000_noag193-B30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026091211370571000_noag193-B31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"2026091211370571000_noag193-B32","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","article-title":"A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"key":"2026091211370571000_noag193-B33","doi-asserted-by":"publisher","first-page":"e39984","DOI":"10.1016\/j.heliyon.2024.e39984","article-title":"Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"2026091211370571000_noag193-B34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","article-title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts","volume":"11","author":"Kitange","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026091211370571000_noag193-B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"key":"2026091211370571000_noag193-B36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1634\/theoncologist.2017-0501","article-title":"Phase II study of bevacizumab and vorinostat for patients with recurrent world health organization grade 4 malignant glioma","volume":"23","author":"Ghiaseddin","year":"2018","journal-title":"Oncologist"},{"key":"2026091211370571000_noag193-B37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026091211370571000_noag193-B38","first-page":"615","article-title":"Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res"},{"key":"2026091211370571000_noag193-B39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026091211370571000_noag193-B40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026091211370571000_noag193-B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fsurg.2016.00021","article-title":"Cancer stem cell hierarchy in glioblastoma multiforme","volume":"3","author":"Bradshaw","year":"2016","journal-title":"Front Surg"},{"key":"2026091211370571000_noag193-B42","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-09-2505","article-title":"CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma","volume":"70","author":"Xu","year":"2010","journal-title":"Cancer Res"},{"key":"2026091211370571000_noag193-B43","doi-asserted-by":"publisher","first-page":"e9930","DOI":"10.15252\/emmm.201809930","article-title":"A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells","volume":"11","author":"Arfaoui","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026091211370571000_noag193-B44","doi-asserted-by":"publisher","first-page":"111202","DOI":"10.1016\/j.cbi.2024.111202","article-title":"The role of ALDH1A1 in glioblastoma proliferation and invasion","volume":"402","author":"Huang","year":"2024","journal-title":"Chem Biol Interact"},{"key":"2026091211370571000_noag193-B45","first-page":"1471","article-title":"Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis","volume":"5","author":"Xu","year":"2015","journal-title":"Am J Cancer Res"},{"key":"2026091211370571000_noag193-B46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1535-7163.MCT-19-0242","article-title":"ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2 (-\/-) ovarian cancer cells","volume":"19","author":"Liu","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026091211370571000_noag193-B47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/neuonc\/nos270","article-title":"Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma","volume":"14","author":"Schafer","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026091211370571000_noag193-B48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","article-title":"Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma","volume":"24","author":"Bhat","year":"2013","journal-title":"Cancer Cell"},{"key":"2026091211370571000_noag193-B49","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.7150\/thno.48314","article-title":"The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"2026091211370571000_noag193-B50","doi-asserted-by":"publisher","first-page":"56199","DOI":"10.18632\/oncotarget.14147","article-title":"A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors","volume":"8","author":"Deutsch","year":"2017","journal-title":"Oncotarget"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag193\/70708879\/noag193.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag193\/70708879\/noag193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:37:14Z","timestamp":1789227434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag193\/8766019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag193","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"noag193"}}